8-K: Hologic Q1 Fiscal 2026 Results Amidst Blackstone/TPG Merger Vote

Hologic reports mixed Q1 FY26 financial results as stockholders prepare to vote on the proposed acquisition by Blackstone and TPG.

Summary

• Reported Q1 FY26 revenue of $1,047.8 million, a 2.5% increase (1.3% constant currency) compared to the prior year.
• GAAP diluted EPS decreased (9.2%) to $0.79, primarily due to favorable foreign exchange gains in the prior year period.
• Non-GAAP diluted EPS increased 1.0% to $1.04.
• Organic revenue, excluding COVID-19 and certain divested/acquired businesses, grew 2.9% (1.6% constant currency).
• Cash flow from operations increased 21.4% to $229.9 million.
• A special meeting of stockholders is scheduled for February 5, 2026, to vote on adopting the merger agreement with funds managed by Blackstone and TPG.
• The company is not providing annual or quarterly financial guidance for fiscal 2026 due to the pending acquisition.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, primarily driven by overall revenue growth and strong cash flow, despite a decline in GAAP EPS and margin pressure from tariffs. The pending acquisition by Blackstone and TPG overshadows the quarterly performance, making the merger vote the more critical near-term event.

Positives

• Total revenue increased by 2.5% to $1,047.8 million for the quarter.
• Non-GAAP diluted EPS grew by 1.0% to $1.04.
• Cash flow from operations significantly increased by 21.4% to $229.9 million.
• Surgical revenue grew 8.7% (7.5% constant currency), driven by increased sales of the acquired Gynesonics business, MyoSure, and Fluent.
• Skeletal Health revenue saw substantial growth of 69.0% (65.9% constant currency).
• Interventional Breast Solutions revenue increased 9.6% (8.4% constant currency).
• Ended the quarter with strong cash and cash equivalents of $2.17 billion and an adjusted net leverage ratio of 0.3 times.

Negatives

• GAAP diluted EPS decreased by (9.2%) to $0.79, mainly due to favorable foreign exchange gains in the prior year period.
• GAAP gross margin decreased by (80) basis points to 56.0%, and non-GAAP gross margin decreased by (150) basis points to 60.1%, primarily due to increased tariff expenses of $15.3 million.
• Non-GAAP operating margin decreased by (40) basis points to 29.0%.
• GAAP net income decreased by (10.9%) to $179.1 million.
• Diagnostics revenue decreased by (1.3%) (or (2.7%) in constant currency).
• Molecular diagnostics revenue decreased by (3.5%) (or (4.6%) in constant currency), driven primarily by lower sales of COVID-19 tests and legacy assays for sexually transmitted infections.
• COVID-19 revenue, including assays and related products, decreased by (35.8%) (or (36.3%) in constant currency).
• Breast imaging revenue decreased by (0.6%) (or (1.6%) in constant currency).

Risks

• The timing, receipt, and terms and conditions of any required governmental and regulatory approvals of the proposed transaction could delay the consummation of the proposed transaction or cause the parties to abandon it.
• There is a possibility that Hologic stockholders may not approve the proposed transaction.
• The risk of any unexpected costs or expenses resulting from the proposed transaction.
• The risk of any litigation relating to the proposed transaction.
• The proposed transaction and its announcement could have adverse effects on the market price of Hologic's common stock, the ability to retain and hire key personnel, and to maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships.
• The risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.
• Ability to obtain and maintain regulatory approvals and clearances for products and maintain compliance with complex and evolving regulations and quality standards.
• Products may contain undetected errors or defects or otherwise not perform as anticipated.
• Impact and costs and expenses of investigative and legal proceedings and compliance risks.
• Impact of future tax legislation.
• Ability to successfully manage ongoing organizational and strategic changes, including attracting, motivating, and retaining key employees.
• Ongoing and possible future effects of global challenges, including macroeconomic uncertainties such as inflation, bank failures, government shutdowns, rising interest rates, and availability of capital markets, wars, conflicts, and recession concerns.
• The effect of worldwide political and social uncertainty and divisions, including the impact on trade regulations and tariffs, which may adversely impact the cost and sale of products or increase costs to purchase materials.
• Risks related to conducting business internationally.
• Ability to execute acquisitions and the impact and anticipated benefits of completed and future acquisitions.
• Risks related to the development of new or improved competitive technologies and products.
• Risks related to the anticipated development of markets and the success of products in these markets.
• Risks related to the ability to predict accurately the demand for products and products under development and to develop strategies to address markets successfully.
• The effect of consolidation in the healthcare industry.
• Risks related to the coverage and reimbursement decisions of third-party payors.
• Potential cybersecurity threats and targeted computer crime.
• The possibility of interruptions or delays at manufacturing facilities, or the failure to secure alternative suppliers if any sole source third-party manufacturers fail to supply.
• Ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, as well as cost inflation in materials, packaging, and transportation.
• Ability to consolidate certain manufacturing and other operations on a timely basis and within budget, without disrupting business and to achieve anticipated cost synergies.
• Potential negative impacts resulting from climate change or other environmental, social, and governance and sustainability related matters.
• Risks related to the ability to meet production and delivery schedules for products.
• The effect of any future public health pandemic or other crises.
• Risks related to the ability to protect intellectual property rights.
• Risks related to anticipated trends relating to financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations.
• Compliance with covenants contained in debt agreements.

Future Outlook

Hologic is not providing annual or quarterly financial guidance for fiscal 2026 due to its agreement to be acquired by Blackstone and TPG.

Industry Context

StockSavvy.ai notes that Hologic's mixed Q1 results reflect broader trends in the medical technology sector, particularly the continued normalization and decline in COVID-19 related revenue. The growth in specific segments like Surgical and Skeletal Health indicates strength in core women's health and diagnostic areas, while increased tariff expenses highlight ongoing global trade complexities impacting profitability. The impending acquisition by Blackstone and TPG positions Hologic within a trend of private equity interest in stable, cash-generating healthcare assets.

Stakeholder Impact

• Shareholders: Will vote on the proposed acquisition, with potential impacts on stock value and contingent value rights (CVR) payments.
• Employees: Potential impacts on retention and integration due to the proposed transaction.
• Customers, Vendors, Partners: Relationships may be affected by the proposed transaction.

Next Steps

• A special meeting of stockholders is scheduled for February 5, 2026, to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters.

Key Dates

Recommendation

Given the company is in the process of being acquired by Blackstone and TPG, the stock price is likely to trade in line with the proposed acquisition price, adjusted for the probability and timing of the deal closing. A 'hold' recommendation is appropriate for investors awaiting the outcome of the stockholder vote and the finalization of the merger.

Keywords

Hologic, HOLX, financial results, Q1 2026, earnings, revenue, EPS, Blackstone, TPG, acquisition, merger, medical technology, women's health, diagnostics, breast health, surgical, skeletal health, corporate governance, SEC filing